Cost Per Responder Of Apremilast Versus Etanercept And Adalimumab In Patients With Active Psoriatic Arthritis
Nov 1, 2014, 00:00 AM
10.1016/j.jval.2014.08.2589
https://www.valueinhealthjournal.com/article/S1098-3015(14)04538-0/fulltext
Section Title :
Disease-Specific Studies
Section Order :
290
First Page :
A376
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)04538-0&doi=10.1016/j.jval.2014.08.2589